Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (12899)	9/17/2003 12:56:35 AM
From: axial	Respond to of 14101

Wolf, what I really like to do is take this first 6 month's figures and project them on a US market - a market with direct-to-consumer advertising. Or maybe I'd rather speculate about the impact of these figures on RK's bargaining position with JnJ - or any other potential US distributor - and the upfront attainable. Perhaps extrapolating the impact of strong revenues on the requirements for the next financing is the thing to do. Actually, those aren't things I really like to do. But I like not wondering if DMX will survive. We have a viable entity here. The bridge to the future is built. The goals are attainable. RK's go-it-alone strategy will pay off. We'll see WF10 brought to the world. All things have become possible. Pennsaid revenues will make a vital contribution to achieving other goals. Pennsaid revenues will be a phenomenon in themselves. You were right. Jim

To: Montana Wildhack who wrote (12899)	9/17/2003 2:28:32 AM
From: Cal Gary	Read Replies (1) \| Respond to of 14101

Wolf How about this: Let's take into account your: It's possible to break that number down further given the 50% growth that the opined 6300 represented. That would be 42. I mean 4200 It simply means less 2003 fiscal Pennsaid revenue from Canada and more Pennsaid scripts in Q1 2004 or 13,537 scripts. I disagree with the 13,000+ answers. * - this is the same methodology being used here and on SH. How would you then calculate Q1 scripts? Now to the "Puzzle": 2003 OXO annual Rev contribution = $316,000 usd Cumm 9mo 2003 European sales = $35,000 usd Therefore Q4 European sales component = $281,000 usd ($281,000 usd = $316,000 - $35,000) This assumes no European Pennsaid sales in 2003 up to this point, but takes care of the entire OXO contribution. Italian Pennsaid has to be European Rev. Q4 2003 Rev = $658,000 usd Less Q4 OXO Rev of $281,000 usd Less Q4 Cdn Pennsaid Rev of $77,000 usd Equals Q4 European Pennsaid Rev of $300,000 usd (using the 2,800 scripts x $38 = $106,400 cdn divided by 1.38 = about $77,000 usd) In my calculations, I do not have any non-Italian European Pennsiad sales. Therefore I can conclude maximum Italian Pennsaid sale is $300,000 usd at the very top end. If I allow for non-Italian European Pennsaid sales, then I denote this as $uk usd. $uk cannot be larger than $300,000 usd, the cap. Then Italian Pennsaid sales = $300,000 usd - $uk usd Have a good evening.